US Stock MarketDetailed Quotes

ACIU AC Immune

Watchlist
  • 3.210
  • -0.190-5.59%
Close Dec 2 16:00 ET
317.61MMarket Cap-7117P/E (TTM)
Pre-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

Comments

    $AC Immune (ACIU.US)$ Reuters· 2 mins ago
    AC Immune Reports Positive Interim Results From Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    $AC Immune (ACIU.US)$
    AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
    AC Immune (NASDAQ: ACIU) announced positive interim results from its Phase 2 VacSYn trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease.
    The treatment showed significant efficacy, inducing anti-a-synuclein antibody levels 16-fold higherthan placebo after 3 immunizations, with a 100% patient response rate.
    The trial rep...
    $AC Immune (ACIU.US)$
    AC Immune Reaches Key Milestone in Alzheimer's Immunotherapy, Receives CHF 24.6M
    Benzinga· 10 mins ago5mins
    AC Immune (ACIU.US)
    3.270
    3.530
    +2.83%
    +7.95%
    AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced that it will receive the second ReTain-related milestone payment (CHF 24.6 million) under its agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson co...
    $AC Immune (ACIU.US)$ Press Release: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    Dow Jones· 7 mins ago
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease
    1
    $AC Immune (ACIU.US)$
    AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease
    AC Immune SA (NASDAQ: ACIU) has received a second milestone payment of CHF 24.6 million from Janssen Pharmaceuticals for the rapid prescreening rate in the Phase 2b ReTain trial of ACI-35.030 (JNJ-2056) for preclinical Alzheimer's disease. This brings the total milestone payments for this trial to CHF 40 million. The potentially regist...
Read more
Trending US Stocks
U.S. Crypto Concept Stocks U.S. Crypto Concept Stocks

Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data. Companies involved in the creation, trade, and services of digital forms of money.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners.Displayed third-party logos, brands, or trademark images on screens or web pages are only for identification purposes and remain the property of their respective owners. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in U.S. Crypto Concept Stocks, ranked from highest to lowest based on real-time market data.